Emily Menendez

GU Oncology Now

The phase 3 <a href="https://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.255" target="_blank" rel="noopener">MIRAGE trial</a> examined the safety and efficacy of both magnetic resonance imaging (MRI)-guided and computed tomography (CT)-guided stereotactic body radiotherapies (SBRTs) for patients with prostate cancer. A recent update published in <a href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2800541" target="_blank" rel="noopener">JAMA Oncology</a> used the trial&rsquo;s conclusions to determine which radiotherapy is most effective.The MIRAGE trial included 156 men with clinically localized prostate adenocarcinoma who were randomized to receive either MRI-guided SBRT or CT-guided SBRT. The trial took place from May 2020 to October 2021, with data analysis occurring from January 2021 to May 2022.During the trial, the occurrence of acute grade 2 or greater genitourinary toxic effects was significantly lower in MRI compared with CT guidance (24.4% vs 43.4%), as was the incidence of acute grade 2 or greater gastrointestinal toxic effects (0.0% vs 10.5%).Patients who received CT-guided SBRT were also more likely to experience increases in urinary symptoms compared with those who received MRI-guided SBRT. MRI guidance was associated with a significantly smaller percentage of patients with a 15-point or greater increase in international prostate symptom scores at 1 month (6.8% vs 19.4%) and a significantly reduced percentage of patients with a clinically significant (&ge;12-point) decrease in their expanded prostate cancer index composite bowel scores (25.0% vs 50.0%) at 1 month.Amar Kishan, MD, the first author of the study and an associate professor and chief of the Genitourinary Oncology Service at UCLA, said the trial authors &ldquo;felt that MRI-guided radiotherapy allows a much tighter margin around the prostate to be targeted due to both the enhanced imaging capabilities of MRI and the ability to track the prostate and control the beam in real time during treatment. The significant reduction in urinary and bowel toxicity seen in our trial reflects the importance and relevance of this tighter margin made possible by MRI-guided radiation therapy.&rdquo;Overall, the MIRAGE trial discovered that MRI-guided SBRT is superior to CT-guided SBRT in reducing acute genitourinary and gastrointestinal toxicity caused by localized prostate cancer. MRI-guided SBRT also results in smaller decrements in urinary and bowel function. However, more long-term follow-up studies are needed to confirm the benefits of MRI-guided SBRT.

MRI-Guided Versus CT-Guided Stereotactic Body Radiotherapy for Prostate Cancer

Localized

A recent update on the phase 3 MIRAGE trial determined if MRI-guided or CT-guided stereotactic body radiotherapy is most effective for prostate cancer.

MRI Vs CT Stereotactic Body Radiotherapy for Prostate Cancer

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe